X0306 4 2016-02-05 1 0001059790 POZEN INC /NC POZN 0001066867 PAR INVESTMENT PARTNERS LP ONE INTERNATIONAL PLACE SUITE 2401 BOSTON MA 02110 0 0 1 0 0001341061 PAR Group, L.P. ONE INTERNATIONAL PLACE SUITE 2401 BOSTON MA 02110 0 0 1 0 0001051359 PAR CAPITAL MANAGEMENT INC ONE INTERNATIONAL PLACE SUITE 2401 BOSTON MA 02110 0 0 1 0 Common Stock 2016-02-05 4 J 0 3863699 D 0 D These securities are held directly by PAR Investment Partners, L.P. ("PIP"). PAR Group, L.P. ("PAR Group") is the general partner of PIP. PAR Group disclaims beneficial ownership of the securities except to the extent of the pecuniary interest, if any, in such securities as a result of PAR Group's general partner interest in PIP and contingent right to a performance-based advisory fee. PAR Capital Management, Inc. ("PCM") is the general partner of PAR Group which is the general partner of PIP. PCM disclaims beneficial ownership of the securities except to the extent of the pecuniary interest, if any, in such securities as a result of PCM's general partner interest in PAR Group. On February 5, 2016, POZEN, Inc. (the "Issuer") completed a business combination with Tribute Pharmaceuticals Canada Inc. As a result of the business combination, each share of common stock of the Issuer that was owned by PIP was converted into one common share of Aralez Pharmaceuticals Inc. PAR Investment Partners, L.P., by PAR Group, L.P., its General Partner, by PAR Capital Management, Inc., its General Partner, /s/ Steven M. Smith, Chief Operating Officer and General Counsel 2016-02-09 PAR Group, L.P., by PAR Capital Management, Inc., its General Partner, /s/ Steven M. Smith, Chief Operating Officer and General Counsel 2016-02-09 PAR Capital Management, Inc., /s/ Steven M. Smith, Chief Operating Officer and General Counsel 2016-02-09